logo
Plus   Neg
Share
Email

Mylan Gets Final FDA Approval For Pioglitazone Tablets USP - Quick Facts

Mylan Inc. (MYL) announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration or FDA for its Abbreviated New Drug Application or ANDA for Pioglitazone Tablets USP, 15 mg, 30 mg and 45 mg.

The company said that previously it had also received final approval from the FDA for its ANDA for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15 mg/500 mg and 15 mg/850 mg.

These products are the generic versions of Takeda Pharmaceutical Company's Actos Tablets and Actoplus Met Tablets, respectively, and are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has awarded Mylan 180 days of generic marketing exclusivity on both of these products.

Pioglitazone Tablets USP, 15 mg, 30 mg and 45 mg, had U.S. sales of about $2.7 billion, and Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15 mg/500 mg and 15 mg/850 mg, had U.S. sales of about $413 million for the 12 months ending June 30, 2012, according to IMS Health.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Canadian gold miner IAMGOLD Corp. announced a strategic investment in Tradewind Markets, Inc., a financial technology company that uses blockchain to speed up and streamline digital gold trading. The miner did not elaborate on the investment amount, while Tradewind in its statement said it has closed a $10.6 million strategic placement. Bristol-Myers Squibb Co. (BMY) on Thursday increased adjusted earnings guidance for the full-year 2018 to a range of $3.35 to $3.45 per share from the prior range of $3.15 to $3.30 per share. However, the company lowered reported earnings outlook to a range of $2.70 to $2.80 per share from the previously... Snack and beverage giant PepsiCo Inc. (PEP) on Thursday reported an increase in net income for the first quarter, reflecting higher revenues. Both adjusted earnings per share and net revenues for the quarter beat analysts' estimates. The company also reaffirmed its earnings and revenue outlook for...
Follow RTT